Pharma firm Strides Arcolab today said it has received the US health regulator's nod to market Mesna injection used as an anticancer drug.
The company has received the US Food and Drug regulators approval to market Mesna injection, an agent used to reduce problems caused by chemotherapy, Strides Arcolab said in a filing to the Bombay Stock Exchange.
Mesna is the fifth product launched under the partnership between Strides and Sagent Pharmaceuticals wherein Strides is developing and supplying more than 25 injectable products for the US market which would be marketed by Sagent, the filing added.
"This is our second product approval this month and the fifth for the partnership with the Sagent," Strides Arcolab CEO (International Operations) Ravi Seth said.
Mesna would be available in 1 mg per 10 mL multi-dose vials, offered in single pack and in packs of ten, it added.